Data Catalogue

203167 Phase 2a in Psoriasis

Psoriasis Phase 2a clinical study.

Types Clinical Trial Ncit:c71104

ELU-4-EA431B-1

204869 Phase 2a/b in Ulcerative Colitis

Types Clinical Trial Ncit:c71104

ELU-4-907C53-1

Patients with Crohn’s disease or ulcerative colitis diagnosis according to ECCO guidelines and who were prescribed adalimumab or infliximab (original product or biosimilar) were recruited from September 11, 2013 to February 15, 2016. Patients who were not naive to TNF inhibitor therapy or who were treated with corticoids more than 30 mg/day over the last 15 days were excluded.

Types Observational

b4c2ea0c-c48e-11ec-9b1d-acde48001122

ABI-MS

Patients with MS or Clinically Isolated Syndrome (CIS) diagnosis according to McDonald criteria and who were prescribed IFN-beta-1a intramuscularly (IM), IFN-beta-1a subcutaneously (SC), or IFN-beta-1b SC (original product or biosimilar) were recruited from January 30, 2014 to January 22, 2016. Patients who were not naive to IFN-beta were excluded.

Types Observational

91f1a748-c48e-11ec-9b1d-acde48001122

ABI-RA

Patients with RA diagnosis according to 2010 ACR/EULAR criteria and who were prescribed for the first time a BP among the TNF inhibitors adalimumab, infliximab (original product or biosimilar), etanercept, the anti-CD20 antibody rituximab, or the anti-IL6R antibody tocilizumab (administered SC or intravenously) as first-line or second-line therapy were recruited from March 3, 2014 to June 21, 2016. Patients who were not naive for the biotherapy they were given in the study were excluded.

Types Observational

b4c2e822-c48e-11ec-9b1d-acde48001122

AETIONOMY

Study phase: recruitment. For more details, see http://www.aetionomy.eu/content/dam/scai/AETIONOMY/Dokumente/Aetionomy_Newsletter4_web.pdf

Types Observational

dc9ac40c-147a-11eb-b51f-8c8590c45a21

AIMS LEAP Timepoint 1 (T1) and Timepoint 2 (T2)

The Longitudinal European Autism Project (LEAP) is currently the largest study in the world to identify variability in autism in terms of behaviour, cognition, co-occurring conditions, outcomes, brain structure/function and genetics. AIMS-LEAP participants have been followed up longitudinally over time, with the current dataset including Timepoint 1 and Timepoint 2 (approx. 12-24-months apart).

Types Clinical Trial Ncit:c71104

ELU-4-4D20BB-1